Cogent Biosciences, Inc. (COGT) is currently Overvalued by 4210.28%

Cogent Biosciences, Inc. (COGT) appears overvalued by approximately 4210.28% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Downside (live) 4210.28% (from live valuation API)
Confidence (live) 8.5/10 (High conviction overvalued)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$40.01

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Cogent Biosciences, Inc. overvalued or undervalued?

Based on intrinsic value, Cogent Biosciences, Inc. (COGT) looks priced ahead of a cash-flow-based fair value that blends growth, reinvestment needs, and a risk-adjusted discount rate.

Compared to historical valuation, today’s multiple exceeds the range implied by the company’s own five-year average—suggesting the market is more optimistic than its own past pricing of similar fundamentals.

Market expectations embedded in the price imply a demanding bar for execution: revenue cadence, margin stability, and capital returns would need to accelerate to justify a sustained premium versus fair value.

Key metrics

P/E ratio: 47.2x
Revenue growth (TTM y/y): 12%
Profit margin: 22.7%
Fair value (model): Unlock

Next steps

Frequently asked questions — COGT

Is COGT overvalued right now?

Based on our 2026 models, Cogent Biosciences, Inc. (COGT) appears overvalued at $40.01 with roughly 4210.3% downside versus fair value. Confirm with valuation ratios and financials before acting.

What is Cogent Biosciences, Inc.'s intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether COGT trades above or below fair value. At $40.01, Cogent Biosciences, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Cogent Biosciences, Inc.'s intrinsic value calculated?

Tickerplace calculates COGT's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is COGT undervalued right now?

A stock is undervalued when price sits below a supportable fair value range. Check whether COGT's gap aligns with fundamentals using the ratios and financial links on this page.

Peers for COGT: open their overvalued / undervalued view.

Instant valuation answer